Drug intelligence / Profile preview

CAN-1300

Development stage: Preclinical
Lead developer: Canwell Biotech
Modality: Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

CAN-1300 is a small molecule-drug conjugate developed by CanWell Pharma. It is being investigated for the treatment of neoplasms, specifically solid tumors. As of May 2025, its highest global R&D status is preclinical. The precise mechanism of action and molecular targets have not been publicly disclosed. The drug represents an approach that combines a small molecule with a cytotoxic payload to selectively target and kill cancer cells in solid tumors[1].

Other names: CAN-1300CAN1300CAN 1300Project 4 (Small molecule drug conjugate) (Canwell)

Beyond the preview

Go deeper on CAN-1300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAN-1300.

Explore the full profile